Affiliation:
1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
2. Welch Medical Library, School of Medicine, Johns Hopkins University, Baltimore, Maryland
Abstract
Abstract
Background
The World Health Organization (WHO) recommends an additional dose of measles-containing vaccine (MCV) for human immunodeficiency virus (HIV)–infected children receiving highly active antiretroviral therapy following immune reconstitution. We conducted a systematic review to synthesize available evidence regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in HIV-infected adolescents and adults to provide the evidence base for recommendations on the need for measles vaccination.
Methods
We conducted searches of 8 databases through 26 September 2017. Identified studies were screened independently by 2 reviewers.
Results
The search identified 30 studies meeting inclusion criteria. Across studies, measles seroprevalence among HIV-infected adolescents and adults was high (median, 92%; 27 studies), with no significant difference compared to HIV-uninfected participants (10 studies). In 6 studies that evaluated the immunogenicity of MCVs among seronegative HIV-infected adults, measles seropositivity at end of follow-up ranged from 0% to 56% (median, 39%). No severe adverse events were reported following measles vaccination in HIV-infected patients.
Conclusions
Based on similar measles seroprevalence between HIV-infected and HIV-uninfected adolescents and adults, and the low response to vaccination, these studies do not support the need for an additional dose of MCV in HIV-infected adolescents and adults. These findings support WHO guidelines that measles vaccine be administered to potentially susceptible, asymptomatic HIV-infected adults, and may be considered for those with symptomatic HIV infection if not severely immunosuppressed. Measles-susceptible adolescents and adults, regardless of HIV status, may require targeted vaccination efforts to reach critical vaccination thresholds and achieve regional elimination goals.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference42 articles.
1. World Health Organization. Measles, first dose (MCV1) immunization coverage by WHO region. Available at: http://apps.who.int/gho/data/view.main.81100. Accessed 4 September 2018.
2. Progress toward regional measles elimination—worldwide, 2000–2016;Dabbagh;Morb Mortal Weekly Rep,2017
3. Measles and measles immunity in children infected with human immunodeficiency virus;Krasinski;JAMA,1989
4. Lessons and challenges for measles control from unexpected large outbreak, Malawi;Minetti;Emerg Infect Dis,2013
5. Measles vaccines: WHO position paper—April 2017;Wkly Epidemiol Rec,2017
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献